Clinical outcomes of abiraterone acetate (AA) or enzalutamide (E) as first-line therapy (Rx) for men aged ≥75 with metastatic castration-resistant prostate cancer (mCRPC) according to previous use of docetaxel (D) for metastatic castration-sensitive prostate cancer (mCSPC) in a multicenter international registry: A SPARTACUSS – Meet-URO 26 study.

Richard M. Lee‐Ying, Edoardo Francini, Pier Vitale Nuzzo et al.|Journal of Clinical Oncology|2023

Cited by 0